直接口服抗凝药与维生素K拮抗剂的上消化道出血结局相似
这项法国多中心前瞻性研究纳入2498例上消化道出血患者,其中475例(19%)使用口服抗凝药,以VKA为主(267例,56.2%)。6周死亡率VKA组高于DOAC组(16.1% vs 7.8%,P<0.01),但多因素分析仅Charlson指数≥5和院内发生UGIB与死亡独立相关,再出血和非内镜治疗需求与抗凝药类型无关。
要点
- DOAC与VKA的上消化道出血患者再出血和非内镜治疗需求无差异
- VKA组6周死亡率高于DOAC组,但多因素分析未显示抗凝药类型独立相关
- Charlson指数≥5和院内发生UGIB是死亡的独立相关因素
核心结论
- DOAC不改变上消化道出血的结局,其再出血和非内镜治疗需求与VKA相似。
- 合并症和伴随治疗是恶化上消化道出血预后的最重要因素。
研究设计与样本
- 法国综合医院前瞻性多中心研究,为期一年连续纳入所有上消化道出血患者。
- 从队列中提取口服抗凝药治疗患者,共2498例纳入,475例(19%)使用口服抗凝药。
主要发现
- 口服抗凝药患者中VKA为主(267例,56.2%),VKA组肾衰竭和肝硬化更常见。
- 胃镜正常73例(15.3%),消化性溃疡病变为主要出血原因(233例,49%)。
- 内镜治疗128例(26.9%),止血成功74%(95例)。
- 6周死亡率12.4%(59例),VKA组高于DOAC组(16.1% vs 7.8%,P<0.01)。
- 再出血56例(11.8%),非内镜治疗18例(3.8%),均与抗凝药类型无关。
关键数值与推荐
- 多因素分析中仅Charlson指数≥5和院内发生UGIB与死亡独立相关。
临床怎么用
- 对口服抗凝药的上消化道出血患者,应重点关注合并症负担(如Charlson指数≥5)和院内出血事件。
- DOAC与VKA在上消化道出血结局上相似,抗凝药类型本身不决定再出血或非内镜治疗需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increased risk of upper gastrointestinal bleeding (UGIB) related to direct oral anticoagulants (DOACs) as compared to vitamin K antagonists (VKA) remains debated. AIMS: To describe the epidemiology and outcomes of UGIB in patients treated with oral anticoagulants. METHODS: A prospective, multicentre study in French general hospitals enrolled all consecutive patients with UGIB during one year. Patients treated with oral anticoagulants were retrieved from the cohort. Main outcomes were mortality and rebleeding during the first 6 weeks and need for non-endoscopic treatment (surgery or interventional radiology). RESULTS: Among the 2498 patients included, 475 (19%) had an oral anticoagulant, mostly with VKA (267 patients [56.2%]). Baseline characteristics were similar between the groups except for renal failure and cirrhosis that were more prevalent in the VKA group. Gastroscopy was normal in 73 patients (15.3%); peptic lesions were the main cause of UGIB (n = 233, 49%). Endoscopic treatment was performed in 128 patients (26.9%), leading to bleeding resolution in 74% (n = 95). Mortality rate at 6 weeks was 12.4% (59 patients), and was higher in the VKA group compared to DOACs (16.1% vs 7.8%, P < 0.01). By multivariate analysis, only the Charlson index ≥ 5 and UGIB occurrring in in-patients were independently associated with mortality. Rebleeding (56 patients [11.8%]) and need for non-endoscopic treatment (18 patients [3.8%]) were not associated with the type of anticoagulant. CONCLUSION: DOACs do not alter outcomes of UGIB as compared to VKA. Comorbidities and associated treatment are the most important factors worsening the prognosis of UGIB.
引用
- Gouriou C, Bouguen G, Lahmek P, et al. Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists. Aliment Pharmacol Ther. 2021. PMID: 33400827. doi:10.1111/apt.16236
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。